小剂量尿激酶联合尼莫地平治疗频发TIA的临床疗效

The clinical efficacy of low-dose Urokinase combined with Nimodipine in the treatment of Frequent TIA

目的:探讨小剂量尿激酶联合尼莫地平治疗频发短暂性脑缺血发作(TIA)的临床疗效。方法:120例频发TIA患者随机分为联合治疗组(小剂量尿激酶加尼莫地平)、尿激酶组(小剂量尿激酶)、常规对照组(阿司匹林)。观察TIA发作终止的时间、例数及脑梗死、脑出血发生情况。结果:联合治疗组24h内及3d内终止频发TIA发作控制率分别为65.0%和17.5%,尿激酶组分别为50.0%和15.0%,常规对照组分别为30.0%和17.5%,终止发作的时间上早于常规对照组,治愈率也明显高于对照组,差异有统计学意义(P<0.01)。结论:小剂量尿激酶联合尼莫地平治疗频发TIA效果显著,并且安全可靠,值得临床推广应用。

Objective： To investigate the clinical efficacy of low-dose Urokinase combined with Nimodipine in the treatment of frequent transient ischemic attack （TIA）. Methods： 120 cases of frequent TIA patients were randomly divided into combined treatment group （low-dose Urokinase and Nimodipine）, Urokinase group （low-dose Urokinase）, normal control group （Aspirin）. The termination of TIA onset time, number and cases of cerebral infarction, cerebral hemorrhage were observed. Results： The treatment group within 24 hours and 3 days of the termination of seizure frequency of TIA control rates were 65.0% and 17.5%, and Urokinase group were 50.0% and 15.0%, Normal control group were 30.0% and 17.5%, the termination of the timing of onset earlier than the normal control group, the cure rate was also significantly higher, the difference was statistically significant （P〈0.01）. Conclusion： Low-dose urokinase combined with Nimodipine treatment of Frequent TIA results are obvious, and the safe, reliable, worthy of clinical application.